ES2670686T3 - Compuestos que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico - Google Patents

Compuestos que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico Download PDF

Info

Publication number
ES2670686T3
ES2670686T3 ES13811827.8T ES13811827T ES2670686T3 ES 2670686 T3 ES2670686 T3 ES 2670686T3 ES 13811827 T ES13811827 T ES 13811827T ES 2670686 T3 ES2670686 T3 ES 2670686T3
Authority
ES
Spain
Prior art keywords
methyl
hydroxy
amino
ethyl
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13811827.8T
Other languages
English (en)
Inventor
Fabio Rancati
Ian Linney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Application granted granted Critical
Publication of ES2670686T3 publication Critical patent/ES2670686T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto que se selecciona entre el grupo que consiste en: 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)-amino)metil)fenoxi)metil)benzoato de 2-(4-((((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)-2-metilfenoxi)etilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)-metil)fenoxi)metil)benzoato de 2-(4-((((R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)fenoxi)etilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)-metil)fenoxi)metil)benzoato de 2-(2-cloro-4-((((R)-2-hidroxi- 2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)-amino)metil)fenoxi)etilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)-amino)metil)fenoxi)metil)benzoato de 2-(4-((((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)-2-metoxifenoxi)etilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)-metil)fenoxi)metil)benzoato de 2-(2-bromo-4-((((R)-2- hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)-amino)metil)fenoxi)etilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)-metil)fenoxi)metil)benzoato de 2-(2-cloro-3-((((R)-2-hidroxi- 2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)-amino)metil)fenoxi)etilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)-amino)metil)fenoxi)metil)benzoato de 2-((4-((((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)naftalen-1-il)oxi)etilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)-metil)fenoxi)metil)benzoato de 2-(3-cloro-4-((((R)-2-hidroxi- 2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)-amino)metil)fenoxi)etilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)-metil)fenoxi)metil)benzoato de 2-(3-((((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)fenoxi)etilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)-amino)metil)fenoxi)metil)benzoato de 2-(4-((((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)-2,6-dimetilfenoxi)etilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)-carbonil)amino)metil)fenoxi)metil)benzoato de 2-(2-cloro-4-((((R)-2-hidroxi- 2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)-amino)metil)-6-metoxi-fenoxi)etilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)-amino)metil)fenoxi)metil)benzoato de 2-(4-((((R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)-3-metoxifenoxi)etilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)-carbonil)amino)metil)fenoxi)metil)benzoato de 2-(2-bromo-4-((((R)-2- hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)-amino)metil)-5-metoxi-fenoxi)etilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)-amino)metil)-fenoxi)metil)benzoato de 2-(2,6-dicloro-4-((((R)-2- hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)metil)fenoxi)etilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)-metil)fenoxi)metil)benzoato de 2-(2-fluoro-4-((((R)-2- hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)-amino)metil)fenoxi)etilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)-amino)metil)fenoxi)-metil)benzoato de 2-(4-((((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)-2,6-dimetoxifenoxi)etilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)-carbonil)amino)metil)fenoxi)metil)benzoato de 2-(2-cloro-4-((((R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)-amino)metil)-5-metoxi-fenoxi)etilo; 3-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)metil)-fenoxi)metil)benzoato de 4-(2-(((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-etil)bencilo; 4-((3-(fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)metil)-fenoxi)metil)benzoato de 2-fluoro-4-(2-(((R)-2-hidroxi-2- (8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)-amino)etil)bencilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)-metil)fenoxi)metil)benzoato de 4-(2-(((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-etil)-3-metoxibencilo; 3-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)metil)-fenoxi)metil)benzoato de 3-(2-(((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-etil)bencilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)metil)-fenoxi)metil)benzoato de 3-((((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)bencilo; 4-((3-(S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)-metil)fenoxi)metil)benzoato de (6-((((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)piridin-3-il)metilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)-metil)fenoxi)metil)benzoato de (5-((((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)furan-2-il)metilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)metil)-fenoxi)metil)benzoato de 2-fluoro-4-((((R)-2-hidroxi-2- (8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)-amino)metil)bencilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)-metil)fenoxi)metil)benzoato 5-((((R)-2-hidroxi-2-(8-hidroxi- 2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)-2-metoxibencilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)-metil)fenoxi)metil)benzoato de (4-((((R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)furan-2-il)metilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)-metil)fenoxi)metil)benzoato de (5-((((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)tiofen-2-il)metilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)-metil)fenoxi)metil)benzoato de (5-((((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)tiofen-3-il)metilo; 3-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)metil)-fenoxi)metil)benzoato de 3-((((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)bencilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)-metil)fenoxi)metil)benzoato de 4-((((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)-3-metoxibencilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)metil)-fenoxi)metil)benzoato de 3-(4-((((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)fenil)propilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)metil)-fenoxi)metil)benzoato de 4-((((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)fenetilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)-amino)metil)fenoxi)metil)benzoato (1-(3-(((R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-propil)-1H-pirazol-4-il)metilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)-metil)fenoxi)metil)benzoato de 2-(4-((((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)-metil)-1H-pirazol-1-il)etilo; 1-metil-5-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)metil)fenoxi)-metil)-1H-pirazol-3-carboxilato de 4- (((R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)butilo; 4-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)metil)fenoxi)metil)-tiofen-2-carboxilato de 4-(((R)-2-hidroxi- 2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)butilo; 5-((3-((S)-fenil((((R)-quinuclidin-3-iloxi)carbonil)amino)metil)fenoxi)metil)-nicotinato de 4-(((R)-2-hidroxi-2-(8- hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)butilo; ((S)-(3-((3-((4-(((R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)butil)carbamoil)-1-metil-1H-pirazol-5-il)metoxi)-fenil)(fenil)metil)carbamato de (R)-quinuclidin-3-ilo; ((S)-(3-((5-((4-(((R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)butil)carbamoil)furan-2- il)metoxi)fenil)(fenil)-metil)carbamato de (R)-quinuclidin-3-ilo; ((S)-(3-((4-((4-(((R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5-il)etil)amino)butil)carbamoil)oxazol-2- il)metoxi)fenil)(fenil)-metil)carbamato de (R)-quinuclidin-3-ilo y clorhidrato de cloruro de (R)-3-((S)-(3-((5-((4-((R)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-dihidroquinolin-5- il)etilamino)butoxi)carbonil)furan-2-il)metoxi)fenil)(fenil)metilcarbamoiloxi)-1-(2-oxo-2-(tiofen-2-il)etil)-1- azoniabiciclo[2.2.2]octano, o una sal farmacéuticamente aceptable de dicho compuesto.
ES13811827.8T 2012-12-06 2013-12-05 Compuestos que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico Active ES2670686T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12195891 2012-12-06
EP12195891 2012-12-06
PCT/EP2013/075661 WO2014086924A1 (en) 2012-12-06 2013-12-05 Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity

Publications (1)

Publication Number Publication Date
ES2670686T3 true ES2670686T3 (es) 2018-05-31

Family

ID=47323975

Family Applications (2)

Application Number Title Priority Date Filing Date
ES13811827.8T Active ES2670686T3 (es) 2012-12-06 2013-12-05 Compuestos que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico
ES18156043T Active ES2816210T3 (es) 2012-12-06 2013-12-05 Compuestos que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18156043T Active ES2816210T3 (es) 2012-12-06 2013-12-05 Compuestos que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico

Country Status (37)

Country Link
US (2) US8987299B2 (es)
EP (2) EP3345904B1 (es)
JP (1) JP6421989B2 (es)
KR (2) KR102240459B1 (es)
CN (1) CN104822678B (es)
AR (1) AR093825A1 (es)
AU (1) AU2013354043C1 (es)
BR (1) BR112015012730B1 (es)
CA (1) CA2893626C (es)
CL (1) CL2015001483A1 (es)
CO (1) CO7400870A2 (es)
CY (2) CY1120159T1 (es)
DK (2) DK2928889T3 (es)
EA (1) EA030552B1 (es)
ES (2) ES2670686T3 (es)
GE (1) GEP20186839B (es)
HR (2) HRP20180915T1 (es)
HU (2) HUE037944T2 (es)
IL (1) IL239182B (es)
LT (2) LT3345904T (es)
MA (1) MA38147B1 (es)
MX (1) MX369311B (es)
NZ (1) NZ708738A (es)
PE (1) PE20151216A1 (es)
PH (1) PH12015501247B1 (es)
PL (2) PL2928889T3 (es)
PT (2) PT3345904T (es)
RS (2) RS60864B1 (es)
SA (1) SA515360514B1 (es)
SG (2) SG11201504318UA (es)
SI (2) SI3345904T1 (es)
TN (1) TN2015000244A1 (es)
TR (1) TR201808698T4 (es)
TW (1) TWI637954B (es)
UA (1) UA118181C2 (es)
WO (1) WO2014086924A1 (es)
ZA (1) ZA201503965B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
KR102156441B1 (ko) 2012-12-06 2020-09-17 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
EP3345904B1 (en) * 2012-12-06 2020-07-29 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
AU2013360866A1 (en) 2012-12-18 2015-07-02 Almirall, S.A. New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activity
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
MA50487B1 (fr) * 2015-11-16 2021-09-30 Chiesi Farm Spa Procédé de préparation d'une formulation de poudre sèche contenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
WO2017093208A1 (en) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP3484879B1 (en) 2016-07-13 2020-12-30 Chiesi Farmaceutici S.p.A. Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CA2994290C (en) 2017-11-06 2024-01-23 Entech Solution As Method and stimulation sleeve for well completion in a subterranean wellbore
WO2022136206A1 (en) * 2020-12-21 2022-06-30 Intervet International B.V. A process for the preparation of n-(bis(4-methoxyphenyl)methyl)-6-oxo-2-(pyridazin-3-yl)-1,6-dihydropyrimidine-5-carboxamide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2222128A (en) 1937-01-29 1940-11-19 Pure Oil Co Preparation and separation of aromatic hydrocarbons
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
ES2302938T3 (es) 2002-10-11 2008-08-01 Pfizer Inc. Derivados de indol como agonistas beta-2.
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
ES2289691T3 (es) 2004-01-22 2008-02-01 Pfizer, Inc. Derivados de sulfonamida para el tratamiento de enfermedades.
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
US7538141B2 (en) 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
WO2005092840A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Formamide derivatives useful as adrenoceptor
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
WO2006023457A1 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
FR2898640B1 (fr) 2006-03-20 2008-04-25 Siemens Vdo Automotive Sas Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne
EP2080523A1 (en) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprising an antimuscarinic and a long-acting beta-agonist
PT2599778T (pt) 2009-04-23 2017-06-06 Theravance Respiratory Co Llc Compostos de diamida possuindo actividade antagonista do receptor muscarínico e agonista do receptor adrenérgico beta 2
WO2010126025A1 (ja) * 2009-04-30 2010-11-04 帝人ファーマ株式会社 四級アンモニウム塩化合物
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
RU2606121C2 (ru) 2011-06-10 2017-01-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов
HRP20151317T1 (hr) * 2011-06-10 2016-01-01 Chiesi Farmaceutici S.P.A. Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora
KR102156441B1 (ko) * 2012-12-06 2020-09-17 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
EP3345904B1 (en) * 2012-12-06 2020-07-29 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity

Also Published As

Publication number Publication date
MX369311B (es) 2019-11-05
JP6421989B2 (ja) 2018-11-14
IL239182A0 (en) 2015-07-30
MA38147A1 (fr) 2018-03-30
CN104822678A (zh) 2015-08-05
LT3345904T (lt) 2020-09-25
HRP20201435T1 (hr) 2020-11-27
AU2013354043C1 (en) 2017-08-31
PL2928889T3 (pl) 2018-09-28
RS57232B1 (sr) 2018-07-31
EA201590873A1 (ru) 2015-09-30
PL3345904T3 (pl) 2020-12-14
EP3345904A1 (en) 2018-07-11
NZ708738A (en) 2019-02-22
JP2016502557A (ja) 2016-01-28
KR20200027049A (ko) 2020-03-11
WO2014086924A1 (en) 2014-06-12
AU2013354043B2 (en) 2017-06-15
BR112015012730B1 (pt) 2022-07-05
SI2928889T1 (en) 2018-05-31
SG10201704032RA (en) 2017-06-29
RS60864B1 (sr) 2020-11-30
US20150133491A1 (en) 2015-05-14
MA38147B1 (fr) 2018-09-28
HK1212989A1 (zh) 2016-06-24
TWI637954B (zh) 2018-10-11
KR102240459B1 (ko) 2021-04-16
CA2893626C (en) 2021-08-24
CN104822678B (zh) 2017-03-08
AR093825A1 (es) 2015-06-24
SA515360514B1 (ar) 2016-08-30
PH12015501247B1 (en) 2019-02-06
GEP20186839B (en) 2018-04-10
LT2928889T (lt) 2018-06-11
PE20151216A1 (es) 2015-09-08
PT2928889T (pt) 2018-05-29
SG11201504318UA (en) 2015-07-30
TR201808698T4 (tr) 2018-07-23
EA030552B1 (ru) 2018-08-31
EP2928889A1 (en) 2015-10-14
PH12015501247A1 (en) 2015-08-17
BR112015012730A2 (pt) 2017-07-11
CL2015001483A1 (es) 2015-10-23
KR102156443B1 (ko) 2020-09-17
EP2928889B1 (en) 2018-03-21
TW201427976A (zh) 2014-07-16
ZA201503965B (en) 2016-09-28
HRP20180915T1 (hr) 2018-07-27
US8987299B2 (en) 2015-03-24
US9371318B2 (en) 2016-06-21
CY1120159T1 (el) 2018-12-12
MX2015006788A (es) 2015-08-05
CA2893626A1 (en) 2014-06-12
DK3345904T3 (da) 2020-08-31
CO7400870A2 (es) 2015-09-30
CY1123365T1 (el) 2021-12-31
ES2816210T3 (es) 2021-03-31
UA118181C2 (uk) 2018-12-10
US20140161736A1 (en) 2014-06-12
HUE037944T2 (hu) 2018-09-28
HUE051394T2 (hu) 2021-03-01
EP3345904B1 (en) 2020-07-29
SI3345904T1 (sl) 2020-09-30
TN2015000244A1 (en) 2016-10-03
DK2928889T3 (en) 2018-05-22
PT3345904T (pt) 2020-09-07
IL239182B (en) 2018-12-31
KR20150090108A (ko) 2015-08-05

Similar Documents

Publication Publication Date Title
CY1121421T1 (el) Φαρμακοτεχνικες μορφες
PH12012500809A1 (en) Methods and compositions for treating cancer
NZ708738A (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
JP2014526549A5 (es)
JP2016515582A5 (es)
RU2017127135A (ru) Терапевтическое средство против рака желчных протоков
EA201590330A1 (ru) Соли и твердые формы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и включающие их композиции и способы их применения
CA2789665A1 (en) Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
CL2015001257A1 (es) Compuestos derivados de 3-(3-(3,5-bis(trifluorometil)fenil)-1h-1,2,4-triazol-1-il)-hidrazida; composicion farmaceutica; procedimiento para preprar precursores; procedimiento para tratar; uso para tratar trastornos asociados a crm1 tal como trastorno proliferativo, inflamatorio, entre otros (divisional de solicitud n° 225-2014).
BR112015010314A2 (pt) composto ou sais farmaceuticamente aceitáveis ou isômeros dos mesmos, composição farmacêutica secretagogo de insulina ou agente hipoglicêmico, agonista do receptor gpr40, e, método para tratar doenças ou distúrbios
JP2013523733A5 (es)
WO2007103970A3 (en) Compositions and methods for treating respiratory disorders
NZ603231A (en) Cgrp receptor antagonist and its use for treating conditions such as migraine, neuropathic pain and proliferative diseases
NZ599778A (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
PL2684877T3 (pl) Faramceutycznie dopuszczalna sól (e)-n-[4-[[3-chloro-4-(2-pirydylometoksy)fenylo]amino]-3-cyjano-7-etoksy-6-chinolilo]-3-[(2r)-1-metylopirolidyn-2-ylo]prop-2-enamidu, sposób jej otrzymywania i jej medyczne zastosowanie
RU2017116197A (ru) 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера
JP2017505293A5 (es)
HUE047666T2 (hu) Eljárás 2-[4-(4-Klórfenoxi)-2-(trifluormetil)fenil]-1-(1,2,4-triazol-1-il)-2-propanol elõállítására
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
RU2016131875A (ru) Производные n-фениллактама, способные стимулировать нейрогенез, и их применение при лечении заболеваний нервной системы
JP2013523814A5 (es)
JP2017502063A5 (es)
JP2014518212A5 (ja) 化合物及び組成物
JP2012520899A5 (es)
IN2014DN03416A (es)